NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$100.60 -0.86 (-0.85 %)
(As of 11/16/2018 04:00 PM ET)
Previous Close$100.60
Today's Range$99.94 - $102.75
52-Week Range$78.99 - $112.88
Volume512,257 shs
Average Volume508,450 shs
Market Capitalization$6.61 billion
P/E Ratio31.44
Dividend YieldN/A
Beta0.73
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include targeting and compensation services, and pharmaceutical audit suite; brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. The company conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAH
Previous Symbol
CUSIPN/A
Phone919-786-8200

Debt

Debt-to-Equity Ratio1.22
Current Ratio0.89
Quick Ratio0.89

Price-To-Earnings

Trailing P/E Ratio31.44
Forward P/E Ratio25.60
P/E Growth1.47

Sales & Book Value

Annual Sales$2.26 billion
Price / Sales2.89
Cash Flow$4.6424 per share
Price / Cash21.67
Book Value$15.09 per share
Price / Book6.67

Profitability

EPS (Most Recent Fiscal Year)$3.20
Net Income$86.92 million
Net Margins2.37%
Return on Equity25.75%
Return on Assets7.48%

Miscellaneous

Employees15,800
Outstanding Shares64,970,000
Market Cap$6.61 billion
OptionableOptionable

PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences Inc (NASDAQ:PRAH) released its quarterly earnings data on Wednesday, October, 31st. The medical research company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.06. The medical research company earned $717.60 million during the quarter, compared to the consensus estimate of $729.63 million. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The firm's quarterly revenue was up 23.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.88 earnings per share. View PRA Health Sciences' Earnings History.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for PRA Health Sciences.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences updated its FY18 earnings guidance on Wednesday, October, 31st. The company provided earnings per share (EPS) guidance of $4.22-4.27 for the period, compared to the Thomson Reuters consensus estimate of $4.19. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.91 billion.PRA Health Sciences also updated its FY 2018 guidance to $4.22-4.27 EPS.

What price target have analysts set for PRAH?

9 equities research analysts have issued 1-year target prices for PRA Health Sciences' shares. Their forecasts range from $100.00 to $120.00. On average, they anticipate PRA Health Sciences' share price to reach $112.2222 in the next year. This suggests a possible upside of 11.6% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

What is the consensus analysts' recommendation for PRA Health Sciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

Has PRA Health Sciences been receiving favorable news coverage?

Headlines about PRAH stock have trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PRA Health Sciences earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Are investors shorting PRA Health Sciences?

PRA Health Sciences saw a increase in short interest in October. As of October 31st, there was short interest totalling 1,538,009 shares, an increase of 42.8% from the October 15th total of 1,077,059 shares. Based on an average daily volume of 429,098 shares, the days-to-cover ratio is currently 3.6 days. Currently, 2.7% of the company's shares are sold short. View PRA Health Sciences' Current Options Chain.

Who are some of PRA Health Sciences' key competitors?

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the folowing people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 59)
  • Mr. Michael J. Bonello, Exec. VP & CFO
  • Timothy McClain, VP of Legal Affairs
  • Christine Rogers, Director of PR & Corp. Communications
  • Mr. Patrick R. Spine, VP of HR

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.44%), Bank of New York Mellon Corp (3.83%), FMR LLC (3.60%), Eagle Asset Management Inc. (1.67%), Swedbank (1.48%) and Acadian Asset Management LLC (1.45%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

Which institutional investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Panagora Asset Management Inc., Pictet Asset Management Ltd., Allianz Asset Management GmbH, Paloma Partners Management Co, Tygh Capital Management Inc., Vaughan Nelson Investment Management L.P. and Wells Fargo & Company MN. Company insiders that have sold PRA Health Sciences company stock in the last year include David W Dockhorn, Linda Baddour and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

Which institutional investors are buying PRA Health Sciences stock?

PRAH stock was purchased by a variety of institutional investors in the last quarter, including Swedbank, Frontier Capital Management Co. LLC, BlackRock Inc., AQR Capital Management LLC, Laurion Capital Management LP, Bank of New York Mellon Corp, First Trust Advisors LP and Jennison Associates LLC. View Insider Buying and Selling for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $100.60.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $6.61 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is http://www.prahs.com.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]


MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  501
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2018 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel